Cargando…
Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors
Response resistance to the immune checkpoint blockade (ICB) immunotherapy remains a major clinical challenge that may be overcome through the rational combination of ICB and specific targeted therapeutics. One emerging combination strategy is based on sensitizing ICB-refractory tumors with antagonis...
Autores principales: | Rahmy, Sharif, Mishra, Sanket J., Murphy, Sean, Blagg, Brian S. J., Lu, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630337/ https://www.ncbi.nlm.nih.gov/pubmed/36341371 http://dx.doi.org/10.3389/fimmu.2022.1005045 |
Ejemplares similares
-
HSP90 as an emerging barrier to immune checkpoint blockade therapy
por: Tang, Daolin, et al.
Publicado: (2022) -
Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor
por: Khandelwal, Anuj, et al.
Publicado: (2018) -
Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts
por: Kuroyanagi, Gen, et al.
Publicado: (2022) -
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
por: Mbofung, Rina M., et al.
Publicado: (2017) -
Aberrant HSP90 Expression in Lymphocytes and HSP90 Response to Anti-PD-1 Therapy in Lymphoma Patients
por: Albakova, Zarema, et al.
Publicado: (2022)